On our mission to develop better medicines, we have secured some valuable collaborations
Our collaborations and partnerships include:
Genentech
In October 2020, we announced a global license and collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the terms of the agreement, Nykode granted Genentech an exclusive worldwide license to develop and commercialize our individualized cancer vaccine, VB10.NEO.
Regeneron
In November 2021, we entered into a multi-target agreement covering five vaccine research programs, three within cancer vaccines, and two within infectious disease vaccines.
MSD
In December 2022, we entered into a clinical supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive head and neck cancer. Under the terms of the agreement, MSD will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
In May 2024, the agreement was expanded to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy.
Roche
In February 2019, Nykode entered a collaboration with Roche to explore a combination of Nykode’s cancer vaccine VB10 and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with advanced cervical cancer. Both companies retained ownership of their respective compounds during the clinical collaboration. The Phase 2 study enrolled 52 women and was completed in November, 2023.
In May 2023, the agreement was extended to include a two-arm randomized, double-blind, placebo-controlled Phase 2 selection trial to evaluate the efficacy and safety of VB10.16 alone or in combination with atezolizumab (Tecentriq®) in patients with HPV16-positive, PD-L1positive, recurrent or metastatic cervical cancer who are refractory to pembrolizumab with chemotherapy with/without bevacizumab. Nykode and Roche will each maintain ownership of their own compounds in the clinical collaboration.
Pharmajet
In 2015, we entered into a license and supply agreement with Pharmajet for the Stratis (R) needle-free jet-injector.
